Advanced Cell Diagnostics

RNAscope: the RNA answer. The first truly effective platform for detecting RNA in situ, down to the single molecule, with unprecedented specificity.

 

Company Profile


ACD shortens the path to personalized medicine by unlocking the power of RNA biomarkers.

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry.

ACD’s products and services are based on its proprietary RNAscope® technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity.

What is RNAscope?   Why RNAscope?

In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development. These internal and external efforts will continue to position ACD as a leader in molecular diagnostics and companion diagnostics.

The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine

Our award-winning technology detects single RNA molecules in situ–a true breakthrough that opens up a world of new possibilities.

RNAscope® technology overcomes critical hurdles in the identification and validation of biomarkers for research, molecular diagnostics and companion diagnostics. With exceptional levels of sensitivity, specificity, and the ability to multiplex, ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ. In addition, turnaround time for a new assay is reduced to less than three weeks, shortening the path to personalized medicine. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity.

ACD’s RNAscope® assay technology is being adopted by a rapidly growing customer base, which includes world-leading academic institutions, cutting-edge biotechnology companies, and the global top 10 pharmaceutical companies. Explore the left menu to learn more about how our innovative technology can accelerate your research.

Enjoy the webinars here to discover more about ACD.

 

Go to Products


For an overview of RNAscope Research-Use-Only Products, click here
 

All ACD products are for Research-Use-Only!